Labiotech.eu

News and Trends 1 Sep 2022

Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose

Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […]

September 1, 2022 - 2 minutesmins - By Jim Cornall

Futura medical erectile dysfunction medication

News and Trends 31 Aug 2022

Gel treatment for erectile dysfunction receives positive results from clinical trial

Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31). MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It […]

August 31, 2022 - 3 minutesmins - By Liza Laws

acute respiratory distress syndrome pantherna therpeutics inflammatory lung disease

News and Trends 31 Aug 2022

Regulatory approval given to Iceland’s EpiEndo for study of COPD treatment

A treatment for chronic respiratory disorders will be the subject of a clinical trial in Iceland after regulatory and ethics approval was granted. EpiEndo Pharmaceuticals will start a clinical trial of its lipopolysaccharide challenge with lead molecule EP395. Available orally, EP395 is an macrolide or Barriolide with reduced antimicrobial activity which aims to address the […]

August 31, 2022 - 2 minutesmins - By Liza Laws

News and Trends 31 Aug 2022

Anti-cancer drug created from reprogrammed yeast

Engineered yeast cells can synthetically produce the essential cancer medicine vinblastine, an international team of scientists showed in a new study published in Nature. In the summer and fall of 2019, some cancer patients experienced interruptions in their treatment. The reason was a shortage of the drugs vinblastine and vincristine, essential chemotherapeutic medicines for several […]

August 31, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers try to bridge gap in link for patients with salmonella infection and clogged arteries

Researchers from Taiwan have discovered that patients with non-typhoidal salmonella (NTS) have higher aortic calcification and elevated plasma levels, which are an inflammatory biomarker. They say their findings suggest the need for early diagnosis of the condition in patients with atherosclerosis risk factors. NTS is a foodborne bacterium causing gastrointestinal infections and can cause life-threatening […]

August 31, 2022 - 4 minutesmins - By Liza Laws

News and Trends 31 Aug 2022

Compound found in trees has potential to kill drug-resistant bacteria

Researchers say the naturally-occurring compound hydroquinine has bacterial killing activity against several microorganisms. Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers identify possible target for type of sporadic ALS

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

United BioPharma gets FDA approval for phase 2 HIV drug trial

Taiwan-headquartered United BioPharma (UBP) says the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of the study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

Interview 31 Aug 2022

How CDMOs keep pace with trends in advanced therapies

Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO Lonza, sheds light on the latest trends in advanced therapies and how manufacturers are keeping up. In 2021, global funding going to cell and gene […]

August 31, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 31 Aug 2022

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal product for both localized and diffuse types of the disease by the European Medicines Agency (EMA). No systemic treatments have been approved for TGCT in […]

August 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Laverock Therapeutics created to develop next generation of programmable cell therapies

Laverock Therapeutics Ltd has been founded to develop a gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the U.K. company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of its senior management team. Laverock Therapeutics started out […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS

Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose

Gel treatment for erectile dysfunction receives positive results from clinical trial

Regulatory approval given to Iceland’s EpiEndo for study of COPD treatment

Anti-cancer drug created from reprogrammed yeast

Researchers try to bridge gap in link for patients with salmonella infection and clogged arteries

Compound found in trees has potential to kill drug-resistant bacteria

Researchers identify possible target for type of sporadic ALS

United BioPharma gets FDA approval for phase 2 HIV drug trial

How CDMOs keep pace with trends in advanced therapies

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

Laverock Therapeutics created to develop next generation of programmable cell therapies

Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!